TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improved Accessibility of EmONC Services for Maternal and Newborn Health: a Community Based Project.
Brief Summary: The purpose of this study is to determine whether an integrated EmONC package (community mobilization, training of community-based health care providers and a maternal and neonatal health pack) reduce perinatal and neonatal mortality.


Options:
A: Intervention Type: BEHAVIORAL; Name: Improved management of severe neonatal infections; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Co-Trimoxazole; TMP-SMZ; Assigned to Arm(s): N/A
C: Arm Label: EmONC package; Type: EXPERIMENTAL; Interventions: Behavioral: EmONC package | Arm Label: Standard of care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: EmONC package; Assigned to Arm(s): EmONC package
D: Arm Label: experimental; Type: EXPERIMENTAL; Interventions: Behavioral: training | Intervention Type: BEHAVIORAL; Name: training; Assigned to Arm(s): experimental

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Tele-rehabilitation of Heart Patients
Brief Summary: The idea behind the Teledi@log consortium is to develop tele-rehabilitation concepts and technologies so that all types of heart disease patients, regardless of degree of severity, can be offered individual, customized and coordinated tele-rehabilitation across sectors. The project is innovative, breaking new ground in relation to existing national and international research projects in the area. The Teledi@log consortium sees its major task as developing and testing scenarios which can lead to a more coherent rehabilitation for heart patients in areas such as patient training, organization across the boundaries of the health system and using tele-rehabilitation technology. The Teledi@log consortium seeks to develop new tele-rehabilitation concepts which bring the patient closer to the health system and thereby promote the heart patient's rehabilitation, giving the patient and their families a more active role via new tele-rehabilitation technologies.The hypothesis of the study is that heart patients participating in a telerehabilitation program will have a higher quality of life compared to heart patients following traditional rehabilitation activities.


Options:
A: Arm Label: Cardio fit; Type: EXPERIMENTAL; Interventions: Behavioral: CardioFit | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: CardioFit; Assigned to Arm(s): Cardio fit
B: Arm Label: BESMILE-HF group; Type: EXPERIMENTAL; Interventions: Behavioral: BESMILE-HF program, Drug: Usual medications | Arm Label: Control; Type: OTHER; Interventions: Drug: Usual medications | Intervention Type: BEHAVIORAL; Name: BESMILE-HF program; Assigned to Arm(s): BESMILE-HF group | Intervention Type: DRUG; Name: Usual medications; Assigned to Arm(s): BESMILE-HF group, Control
C: Arm Label: Telerehabilitation programme; Type: EXPERIMENTAL; Interventions: Device: Telerehabilitation programme | Arm Label: Control group traditional rehabilitation; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Telerehabilitation programme; Assigned to Arm(s): Telerehabilitation programme
D: Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Educational website.; Type: EXPERIMENTAL; Interventions: Other: Educational website (in addition to usual care). | Arm Label: Website and interactive platform with telemonitoring.; Type: EXPERIMENTAL; Interventions: Other: Website and interactive platform with telemonitoring. | Intervention Type: OTHER; Name: Educational website (in addition to usual care).; Assigned to Arm(s): Educational website. | Intervention Type: OTHER; Name: Website and interactive platform with telemonitoring.; Assigned to Arm(s): Website and interactive platform with telemonitoring.

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Tele-rehabilitation of Heart Patients
Brief Summary: The idea behind the Teledi@log consortium is to develop tele-rehabilitation concepts and technologies so that all types of heart disease patients, regardless of degree of severity, can be offered individual, customized and coordinated tele-rehabilitation across sectors. The project is innovative, breaking new ground in relation to existing national and international research projects in the area. The Teledi@log consortium sees its major task as developing and testing scenarios which can lead to a more coherent rehabilitation for heart patients in areas such as patient training, organization across the boundaries of the health system and using tele-rehabilitation technology. The Teledi@log consortium seeks to develop new tele-rehabilitation concepts which bring the patient closer to the health system and thereby promote the heart patient's rehabilitation, giving the patient and their families a more active role via new tele-rehabilitation technologies.The hypothesis of the study is that heart patients participating in a telerehabilitation program will have a higher quality of life compared to heart patients following traditional rehabilitation activities.


Options:
A: Arm Label: Weight Loss; Type: EXPERIMENTAL; Interventions: Other: Weight Loss | Arm Label: Interval Training; Type: EXPERIMENTAL; Interventions: Other: Interval Training | Intervention Type: OTHER; Name: Interval Training; Assigned to Arm(s): Interval Training | Intervention Type: OTHER; Name: Weight Loss; Assigned to Arm(s): Weight Loss
B: Arm Label: Telerehabilitation programme; Type: EXPERIMENTAL; Interventions: Device: Telerehabilitation programme | Arm Label: Control group traditional rehabilitation; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Telerehabilitation programme; Assigned to Arm(s): Telerehabilitation programme
C: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Daily feedback | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Financial incentive, Behavioral: Daily feedback | Intervention Type: BEHAVIORAL; Name: Financial incentive; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Daily feedback; Assigned to Arm(s): Control, Intervention
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Rehabilitation in institution | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Rehabilitation at home, Behavioral: Out-patient rehabilitation at the hospital | Intervention Type: BEHAVIORAL; Name: Rehabilitation in institution; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Rehabilitation at home; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Out-patient rehabilitation at the hospital; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Tele-rehabilitation of Heart Patients
Brief Summary: The idea behind the Teledi@log consortium is to develop tele-rehabilitation concepts and technologies so that all types of heart disease patients, regardless of degree of severity, can be offered individual, customized and coordinated tele-rehabilitation across sectors. The project is innovative, breaking new ground in relation to existing national and international research projects in the area. The Teledi@log consortium sees its major task as developing and testing scenarios which can lead to a more coherent rehabilitation for heart patients in areas such as patient training, organization across the boundaries of the health system and using tele-rehabilitation technology. The Teledi@log consortium seeks to develop new tele-rehabilitation concepts which bring the patient closer to the health system and thereby promote the heart patient's rehabilitation, giving the patient and their families a more active role via new tele-rehabilitation technologies.The hypothesis of the study is that heart patients participating in a telerehabilitation program will have a higher quality of life compared to heart patients following traditional rehabilitation activities.


Options:
A: Arm Label: Telerehabilitation programme; Type: EXPERIMENTAL; Interventions: Device: Telerehabilitation programme | Arm Label: Control group traditional rehabilitation; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Telerehabilitation programme; Assigned to Arm(s): Telerehabilitation programme
B: Arm Label: Standard of Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: Telehealth Pulmonary Rehabilitation | Intervention Type: OTHER; Name: Telehealth Pulmonary Rehabilitation; Assigned to Arm(s): Intervention
C: Arm Label: AB sequence; Type: EXPERIMENTAL; Interventions: Other: Usual care followed by the use of HeartHab application | Arm Label: BA sequence; Type: EXPERIMENTAL; Interventions: Other: Use of HeartHab application followed by usual care | Intervention Type: OTHER; Name: Use of HeartHab application followed by usual care; Assigned to Arm(s): BA sequence | Intervention Type: OTHER; Name: Usual care followed by the use of HeartHab application; Assigned to Arm(s): AB sequence
D: Arm Label: BESMILE-HF group; Type: EXPERIMENTAL; Interventions: Behavioral: BESMILE-HF program, Drug: Usual medications | Arm Label: Control; Type: OTHER; Interventions: Drug: Usual medications | Intervention Type: BEHAVIORAL; Name: BESMILE-HF program; Assigned to Arm(s): BESMILE-HF group | Intervention Type: DRUG; Name: Usual medications; Assigned to Arm(s): BESMILE-HF group, Control

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Tele-rehabilitation of Heart Patients
Brief Summary: The idea behind the Teledi@log consortium is to develop tele-rehabilitation concepts and technologies so that all types of heart disease patients, regardless of degree of severity, can be offered individual, customized and coordinated tele-rehabilitation across sectors. The project is innovative, breaking new ground in relation to existing national and international research projects in the area. The Teledi@log consortium sees its major task as developing and testing scenarios which can lead to a more coherent rehabilitation for heart patients in areas such as patient training, organization across the boundaries of the health system and using tele-rehabilitation technology. The Teledi@log consortium seeks to develop new tele-rehabilitation concepts which bring the patient closer to the health system and thereby promote the heart patient's rehabilitation, giving the patient and their families a more active role via new tele-rehabilitation technologies.The hypothesis of the study is that heart patients participating in a telerehabilitation program will have a higher quality of life compared to heart patients following traditional rehabilitation activities.


Options:
A: Arm Label: Aerobic Exercise Program; Type: EXPERIMENTAL; Interventions: Behavioral: Aerobic Exercise Program | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Aerobic Exercise Program; Assigned to Arm(s): Aerobic Exercise Program
B: Arm Label: PATHway; Type: EXPERIMENTAL; Interventions: Behavioral: PATHway | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: PATHway; Assigned to Arm(s): PATHway
C: Arm Label: Telerehabilitation programme; Type: EXPERIMENTAL; Interventions: Device: Telerehabilitation programme | Arm Label: Control group traditional rehabilitation; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Telerehabilitation programme; Assigned to Arm(s): Telerehabilitation programme
D: Arm Label: Enhanced Internet-based intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Tailored content, Behavioral: Generic Internet-based information, Behavioral: Discussion forum, Behavioral: Behavioral monitoring | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Generic Internet-based information, Behavioral: Discussion forum | Intervention Type: BEHAVIORAL; Name: Tailored content; Assigned to Arm(s): Enhanced Internet-based intervention | Intervention Type: BEHAVIORAL; Name: Generic Internet-based information; Assigned to Arm(s): Control, Enhanced Internet-based intervention | Intervention Type: BEHAVIORAL; Name: Discussion forum; Assigned to Arm(s): Control, Enhanced Internet-based intervention | Intervention Type: BEHAVIORAL; Name: Behavioral monitoring; Assigned to Arm(s): Enhanced Internet-based intervention

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: We compared the prophylactic anti-emetic efficacy of ramosetron, a newly developed 5-HT3 antagonist, granisetron and ondansetron in patients at high-risk for postoperative nausea and vomiting after laparoscpic abdominal surgery.

This study was conducted to determine the efficacy of three 5-HT3 receptor antagonists in the prevention of PONV for laparoscopic surgery in patients receiving PCA IV.


Options:
A: Arm Label: Palonosetron group; Type: N/A; Interventions: N/A | Arm Label: Granisetron group; Type: N/A; Interventions: N/A | Arm Label: Ramosetron group; Type: N/A; Interventions: N/A
B: Arm Label: The study group (Gr. D); Type: EXPERIMENTAL; Interventions: Drug: Dexamethasone, Drug: Ondansetron | Arm Label: the control group (Gr. N); Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.9% Sodium Chloride Injection | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): The study group (Gr. D) | Intervention Type: DRUG; Name: Ondansetron; Assigned to Arm(s): The study group (Gr. D) | Intervention Type: DRUG; Name: 0.9% Sodium Chloride Injection; Assigned to Arm(s): the control group (Gr. N)
C: Arm Label: Dexamethasone group; Type: ACTIVE_COMPARATOR; Interventions: Drug: intravenous dexamethasone | Arm Label: Placebo group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Homologated placebo. | Intervention Type: DRUG; Name: intravenous dexamethasone; Assigned to Arm(s): Dexamethasone group | Intervention Type: DRUG; Name: Homologated placebo.; Assigned to Arm(s): Placebo group
D: Arm Label: Group A; Type: ACTIVE_COMPARATOR; Interventions: Drug: ramosetron with saline | Arm Label: Group B; Type: EXPERIMENTAL; Interventions: Drug: ramosetron with dexamethasone | Intervention Type: DRUG; Name: ramosetron with saline; Assigned to Arm(s): Group A | Intervention Type: DRUG; Name: ramosetron with dexamethasone; Assigned to Arm(s): Group B

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Efficacy, Safety and Tolerability up to 5 Years in Patients With Active Psoriatic Arthritis
Brief Summary: This study was to provide 24 - 52 week efficacy, safety and tolerability data to support the registration of the secukinumab (AIN457) prefilled syringe (PFS) for subcutaneous self administration in subjects with active PsA despite current or previous NSAID, DMARD and/or anti-TNFα therapy. An additional 4 years of long-term efficacy and safety data were collected during the post Week 52 period of the study.


Options:
A: Arm Label: Infliximab + methotrexate (IFX + MTX); Type: EXPERIMENTAL; Interventions: Drug: Infliximab + methotrexate (IFX + MTX) | Arm Label: Methotrexate (MTX); Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate (MTX) | Intervention Type: DRUG; Name: Infliximab + methotrexate (IFX + MTX); Assigned to Arm(s): Infliximab + methotrexate (IFX + MTX) | Intervention Type: DRUG; Name: Methotrexate (MTX); Assigned to Arm(s): Methotrexate (MTX)
B: Arm Label: psoriatic arthritis (PsA) questionnaire; Type: NO_INTERVENTION; Interventions: Procedure: lab draws and imaging | Intervention Type: PROCEDURE; Name: lab draws and imaging; Assigned to Arm(s): psoriatic arthritis (PsA) questionnaire
C: Arm Label: Secukinumab (AIN457) 75 mg s.c.; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab (AIN457) | Arm Label: Secukinumab (AIN457) 150 mg s.c.; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab (AIN457) | Arm Label: Secukinumab (AIN457) 300 mg s.c.; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab (AIN457) | Arm Label: Placebo s.c.; Type: PLACEBO_COMPARATOR; Interventions: Drug: Secukinumab (AIN457), Drug: Placebo | Intervention Type: DRUG; Name: Secukinumab (AIN457); Assigned to Arm(s): Placebo s.c., Secukinumab (AIN457) 150 mg s.c., Secukinumab (AIN457) 300 mg s.c., Secukinumab (AIN457) 75 mg s.c. | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo s.c.
D: Arm Label: Treatment Group 1: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Golimumab | Arm Label: Treatment Group 2: Golimumab; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: Golimumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Treatment Group 1: Placebo, Treatment Group 2: Golimumab | Intervention Type: DRUG; Name: Golimumab; Assigned to Arm(s): Treatment Group 1: Placebo, Treatment Group 2: Golimumab

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Efficacy, Safety and Tolerability up to 5 Years in Patients With Active Psoriatic Arthritis
Brief Summary: This study was to provide 24 - 52 week efficacy, safety and tolerability data to support the registration of the secukinumab (AIN457) prefilled syringe (PFS) for subcutaneous self administration in subjects with active PsA despite current or previous NSAID, DMARD and/or anti-TNFα therapy. An additional 4 years of long-term efficacy and safety data were collected during the post Week 52 period of the study.


Options:
A: Arm Label: 210 mg brodalumab; Type: EXPERIMENTAL; Interventions: Drug: 210 mg brodalumab, Drug: placebo | Arm Label: 140 mg brodalumab; Type: EXPERIMENTAL; Interventions: Drug: 140 mg brodalumab, Drug: placebo | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: 210 mg brodalumab, Drug: placebo | Intervention Type: DRUG; Name: 210 mg brodalumab; Assigned to Arm(s): 210 mg brodalumab, placebo | Intervention Type: DRUG; Name: 140 mg brodalumab; Assigned to Arm(s): 140 mg brodalumab | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 140 mg brodalumab, 210 mg brodalumab, placebo
B: Arm Label: Secukinumab (AIN457) 75 mg s.c.; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab (AIN457) | Arm Label: Secukinumab (AIN457) 150 mg s.c.; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab (AIN457) | Arm Label: Secukinumab (AIN457) 300 mg s.c.; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab (AIN457) | Arm Label: Placebo s.c.; Type: PLACEBO_COMPARATOR; Interventions: Drug: Secukinumab (AIN457), Drug: Placebo | Intervention Type: DRUG; Name: Secukinumab (AIN457); Assigned to Arm(s): Placebo s.c., Secukinumab (AIN457) 150 mg s.c., Secukinumab (AIN457) 300 mg s.c., Secukinumab (AIN457) 75 mg s.c. | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo s.c.
C: Arm Label: ustekinumab 45 mg; Type: EXPERIMENTAL; Interventions: Drug: ustekinumab | Arm Label: ustekinumab 90 mg; Type: EXPERIMENTAL; Interventions: Drug: ustekinumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: ustekinumab; Assigned to Arm(s): ustekinumab 45 mg, ustekinumab 90 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: Etanercept 50 mg; Type: EXPERIMENTAL; Interventions: Drug: Etanercept | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): Etanercept 50 mg

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Efficacy, Safety and Tolerability up to 5 Years in Patients With Active Psoriatic Arthritis
Brief Summary: This study was to provide 24 - 52 week efficacy, safety and tolerability data to support the registration of the secukinumab (AIN457) prefilled syringe (PFS) for subcutaneous self administration in subjects with active PsA despite current or previous NSAID, DMARD and/or anti-TNFα therapy. An additional 4 years of long-term efficacy and safety data were collected during the post Week 52 period of the study.


Options:
A: Arm Label: Etanercept; Type: EXPERIMENTAL; Interventions: Drug: Etanercept | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): Etanercept
B: Arm Label: Placebo (Part A); Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo for risankizumab | Arm Label: Risankizumab 75 mg (Part A); Type: EXPERIMENTAL; Interventions: Drug: risankizumab, Drug: placebo for risankizumab | Arm Label: Risankizumab 150 mg (Part A); Type: EXPERIMENTAL; Interventions: Drug: risankizumab | Intervention Type: DRUG; Name: risankizumab; Assigned to Arm(s): Risankizumab 150 mg (Part A), Risankizumab 75 mg (Part A) | Intervention Type: DRUG; Name: placebo for risankizumab; Assigned to Arm(s): Placebo (Part A), Risankizumab 75 mg (Part A)
C: Intervention Type: DRUG; Name: TNF-alpha antagonists; Assigned to Arm(s): N/A
D: Arm Label: Secukinumab (AIN457) 75 mg s.c.; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab (AIN457) | Arm Label: Secukinumab (AIN457) 150 mg s.c.; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab (AIN457) | Arm Label: Secukinumab (AIN457) 300 mg s.c.; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab (AIN457) | Arm Label: Placebo s.c.; Type: PLACEBO_COMPARATOR; Interventions: Drug: Secukinumab (AIN457), Drug: Placebo | Intervention Type: DRUG; Name: Secukinumab (AIN457); Assigned to Arm(s): Placebo s.c., Secukinumab (AIN457) 150 mg s.c., Secukinumab (AIN457) 300 mg s.c., Secukinumab (AIN457) 75 mg s.c. | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo s.c.

Answer: D